Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PML_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PML_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PML_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PML_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PML_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000155820 | Skin | AK | regulation of cell growth | 73/1910 | 414/18723 | 2.21e-06 | 6.27e-05 | 73 |
GO:004328127 | Skin | AK | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 44/1910 | 209/18723 | 2.38e-06 | 6.65e-05 | 44 |
GO:007156010 | Skin | AK | cellular response to transforming growth factor beta stimulus | 50/1910 | 250/18723 | 2.45e-06 | 6.76e-05 | 50 |
GO:19019907 | Skin | AK | regulation of mitotic cell cycle phase transition | 57/1910 | 299/18723 | 2.47e-06 | 6.76e-05 | 57 |
GO:000931420 | Skin | AK | response to radiation | 78/1910 | 456/18723 | 3.32e-06 | 8.59e-05 | 78 |
GO:19019877 | Skin | AK | regulation of cell cycle phase transition | 69/1910 | 390/18723 | 3.69e-06 | 9.11e-05 | 69 |
GO:003304410 | Skin | AK | regulation of chromosome organization | 40/1910 | 187/18723 | 4.47e-06 | 1.07e-04 | 40 |
GO:20000457 | Skin | AK | regulation of G1/S transition of mitotic cell cycle | 33/1910 | 142/18723 | 4.71e-06 | 1.12e-04 | 33 |
GO:000072320 | Skin | AK | telomere maintenance | 31/1910 | 131/18723 | 6.10e-06 | 1.39e-04 | 31 |
GO:00182058 | Skin | AK | peptidyl-lysine modification | 66/1910 | 376/18723 | 7.80e-06 | 1.72e-04 | 66 |
GO:003220418 | Skin | AK | regulation of telomere maintenance | 22/1910 | 80/18723 | 1.08e-05 | 2.28e-04 | 22 |
GO:003459927 | Skin | AK | cellular response to oxidative stress | 53/1910 | 288/18723 | 1.56e-05 | 3.05e-04 | 53 |
GO:003087915 | Skin | AK | mammary gland development | 31/1910 | 137/18723 | 1.60e-05 | 3.09e-04 | 31 |
GO:200125220 | Skin | AK | positive regulation of chromosome organization | 22/1910 | 82/18723 | 1.65e-05 | 3.16e-04 | 22 |
GO:000961519 | Skin | AK | response to virus | 63/1910 | 367/18723 | 2.53e-05 | 4.54e-04 | 63 |
GO:004275210 | Skin | AK | regulation of circadian rhythm | 28/1910 | 121/18723 | 2.62e-05 | 4.65e-04 | 28 |
GO:19028066 | Skin | AK | regulation of cell cycle G1/S phase transition | 35/1910 | 168/18723 | 3.11e-05 | 5.26e-04 | 35 |
GO:001095226 | Skin | AK | positive regulation of peptidase activity | 39/1910 | 197/18723 | 3.82e-05 | 6.31e-04 | 39 |
GO:005079226 | Skin | AK | regulation of viral process | 34/1910 | 164/18723 | 4.45e-05 | 7.03e-04 | 34 |
GO:00427709 | Skin | AK | signal transduction in response to DNA damage | 35/1910 | 172/18723 | 5.20e-05 | 8.05e-04 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PML | SNV | Missense_Mutation | novel | c.1022C>T | p.Ser341Leu | p.S341L | P29590 | protein_coding | deleterious(0.03) | probably_damaging(0.983) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PML | SNV | Missense_Mutation | | c.1228N>G | p.Pro410Ala | p.P410A | P29590 | protein_coding | tolerated(0.06) | probably_damaging(0.95) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PML | deletion | Frame_Shift_Del | | c.208delN | p.Leu70CysfsTer28 | p.L70Cfs*28 | P29590 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PML | SNV | Missense_Mutation | rs769540520 | c.2221N>T | p.Arg741Cys | p.R741C | P29590 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PML | SNV | Missense_Mutation | rs765869727 | c.973C>T | p.Arg325Cys | p.R325C | P29590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PML | SNV | Missense_Mutation | | c.895G>C | p.Glu299Gln | p.E299Q | P29590 | protein_coding | tolerated(0.23) | benign(0.3) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
PML | SNV | Missense_Mutation | | c.1702N>A | p.Glu568Lys | p.E568K | P29590 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | | c.502N>A | p.Glu168Lys | p.E168K | P29590 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | novel | c.1015N>A | p.Tyr339Asn | p.Y339N | P29590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | rs745678082 | c.2218N>A | p.Glu740Lys | p.E740K | P29590 | protein_coding | tolerated(0.2) | benign(0.007) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | GEMTUZUMAB OZOGAMICIN | | 15187030 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TRETINOIN | TRETINOIN | 21505136,8674046,21613260,23670176,11704842,30289902 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | arsenic trioxide | | 24433361 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | tretinoin | TRETINOIN | |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TAMIBAROTENE | TAMIBAROTENE | 30289902 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TAZAROTENE | TAZAROTENE | 16939905 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | Tretinoin | TRETINOIN | |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARSENIC TRIOXIDE | | 26537301,11704842 |